Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment

Current Pharmaceutical Design

Volumn 16, Issue 19, 2010, Pages 2076-2090

  Krampe, Henning ^a   Ehrenreich, Hannelore ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Addiction; Alcohol dependence; Alcohol deterrents; Alcoholism treatment; Antabuse; Disulfiram; Pharmacotherapy; Psychotherapy

Indexed keywords

4 HYDROXYBUTYRIC ACID; ACAMPROSATE; AMITRIPTYLINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CALCIUM CARBIMIDE; CEFUROXIME AXETIL; CHLORDIAZEPOXIDE; DIAZEPAM; DISULFIRAM; IMIPRAMINE; ISONIAZID; METRONIDAZOLE; NALTREXONE; PERPHENAZINE; PHENAZONE; PHENYTOIN; PLACEBO; RIFAMPICIN; THEOPHYLLINE; TOPIRAMATE; TRANYLCYPROMINE; TRIAZOLAM; WARFARIN; DRUGS USED IN THE TREATMENT OF ADDICTION;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADD ON THERAPY; ALCOHOLISM; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; COPING BEHAVIOR; DELIRIUM; DERMATITIS; DIARRHEA; DISULFIRAM ETHANOL REACTION; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECZEMA; EXFOLIATIVE DERMATITIS; FATIGUE; HALITOSIS; HEART DISEASE; HEPATITIS; HUMAN; HYPOTENSION; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; LUNG CANCER; MANIC PSYCHOSIS; NAUSEA; NEOPLASM; NEURITIS; NEUROPATHY; OPTIC NERVE DISEASE; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; PRURITUS; PSYCHOEDUCATION; PSYCHOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; ST SEGMENT DEPRESSION; STOMACH DISCOMFORT; TREATMENT OUTCOME; VOMITING; ADAPTIVE BEHAVIOR; ANIMAL; DIRECTLY OBSERVED THERAPY; DOSE RESPONSE; MEDICATION COMPLIANCE; MULTIMODALITY CANCER THERAPY; PROCEDURES;

ADAPTATION, PSYCHOLOGICAL; ALCOHOL DETERRENTS; ALCOHOLISM; ANIMALS; COMBINED MODALITY THERAPY; DIRECTLY OBSERVED THERAPY; DISULFIRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEDICATION ADHERENCE; PSYCHOTHERAPY;

EID: 77955643957     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791516431     Document Type: Review

References (106)

1. Schuckit MA. Drug and alcohol abuse: a clinical guide to diagnosis and treatment. 5th ed. New York: Kluwer Academic/Plenum Publishers 2000.
2. Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcoholuse disorders. Lancet 2009; 373: 2223-3.
3. Jacobi F, Wittchen HU, Hoelting C, et al. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med 2004; 34(4): 597-611.
4. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Study. Arch Gen Psychiatry 1994; 51(1): 8-19.
5. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264(19): 2511-8.
6. Krampe H, Stawicki S, Hoehe MR, et al. Outpatient Long-term Intensive Therapy for Alcoholics (OLITA): a successful biopsychosocial approach to the treatment of alcoholism. Dialog Clin Neurosci 2007; 9(4): 399-412.
7. Rehm J, Room R, Vandenbrink W, et al. Alcohol use disorders in EU countries and Norway: An overview of the epidemiology. Eur Neuropsychopharmacol 2005; 15: 377-88.
8. O'Brien CP, McLellan AT. Myths about the treatment of addiction. Lancet 1996; 347: 237-40.
9. Brewer C. Supervised disulfiram is more effective in alcoholics than naltrexone or acamprosate -or even psychotherapy: how it works and why it matters. Adicciones 2005; 17(4): 285-96.
10. Ehrenreich H, Krampe H. Does disulfiram have a role in alcoholism treatment today? Not to forget about disulfiram's psychological effects. Addiction 2004; 99(1): 26-7.
11. Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today? Addiction 2004; 99(1): 21-4.
12. Hughes JC, Cook CCH. The efficacy of disulfiram - a review of outcome studies. Addiction 1997; 92(4): 381-95.
13. Krampe H, Stawicki S, Wagner T, et al. Follow-up of 180 chronic alcoholic patients for up to seven years after outpatient treatment: Impact of alcohol deterrents on outcome. Alcohol Clin Exp Res 2006; 30(1): 86-95.
14. Suh J, Pettinati H, Kampman K, et al. The status of disulfiram: a half of a century later. J Clin Psychopharmacol 2006; 26(3): 290- 302.
15. Banys P. The clinical use of disulfiram (Antabuse): a review. J Psychoactive Drugs 1988; 20(3): 243-61.
16. Williams E. Effects of alcohol on workers with carbon disulfide. JAMA 1937; 109(18): 1472-3.
17. Hald J, Jacobsen E. A drug sensitising the organism to ethyl alcohol. Lancet 1948; 255: 1001-4.
18. Martensen-Larsen O. Treatment of alcoholism with a sensitising drug. Lancet 1948; 255: 1004-5.
19. Hald J, Jacobsen E, Larsen V. The sensitizing effect of tetraethylthiuramdisulfide (Antabuse) to ethyl alcohol. Acta Pharmacol Toxicol (Copenh) 1948; 4: 285-96.
20. Carmen B, Angeles M, Ana M, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99(7): 811-28.
21. O'Brien CP. Anticraving medications for relapse prevention: A possible new class of psychoactive medications. Am J Psychiatry 2005; 162: 1423-31.
22. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis. Alcohol Clin Exp Res Sep 2001; 25(9): 1335-41.
23. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis. Alcohol Clin Exp Res 2004; 28(1): 51-63.
24. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005; 8(2): 267-80.
25. Anton RF, Swift RM. Current pharmacotherapies of alcoholism: A U. S. perspective. Am J Addict 2003; 12(Suppl 1): S53-68.
26. Soyka M. Relapse prevention in alcoholism - recent advances and future possibilities. CNS Drugs 1997; 7(4): 313-27.
27. Kranzler HR. Pharmacotherapy of alcoholism: Gaps in knowledge and opportunities for research. Alcohol Alcohol 2000; 35(6): 537- 47.
28. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003-17.
29. Vocci F, Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr Opin Psychiatry 2005; 18: 265-70.
30. Karila L, Gorelick D, Weinstein A, et al. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 2008; 11: 425-38.
31. Preti A. New developments in the pharmacotherapy of cocaine abuse. Addict Biol 2007; 12: 133-51.
32. Weinshenker D, Schroeder J. There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology 2007; 32: 1433-51.
33. De Sousa A, De Sousa A. A one-year pragmatic trial of naltrexone versus disulfiram in the treatment of alcohol dependence. Alcohol Alcohol 2004; 39(6): 528-31.
34. De Sousa A, De Sousa A. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 2005; 40(6): 545-8.
35. Petrakis I, Poling J, Levinson C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 2005; 57: 1128-37.
36. Nava F, Premi S, Manzato E, et al. Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptions. J Psychoactive Drugs 2006; 38(3): 211-7.
37. De Sousa A, De Sousa A. An open randomized trial comparing disulfiram and naltrexone in adolescents with alcohol dependence. J Subst Use 2008; 3(6): 382-8.
38. De Sousa A, De Sousa J, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat 2008; 34: 460-3.
39. Laaksonen E, Koski-Jaennes A, Salaspuro M, et al. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 2008; 43(1): 53-61.
40. Berglund M. A better widged? Three lessons for improving addiction treatment from a meta-analytical study. Addiction 2005; 100: 742-50.
41. Soyka M, Kranzler H, Berglund M, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 1: alcoholism. World J Biol Psychiatry 2008; 9(1): 6-23.
42. Garbutt J. The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat 2009; 36(Suppl 1): S15-23.
43. Johnson BA. Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Biochem Pharmacol 2008; 75: 34-56.
44. Swift RM. Emerging approaches to managing alcohol dependence. Am J Health Syst Pharm 2007; 64 (Suppl 3): S12-22.
45. Martin B, Beresford T. Disulfiram in context: structure and safety. J Clin Psychopharmacol 2007; 27(4): 415-7.
46. Cvek B, Dvorak Z. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? Drug Discov Today 2008; 13(15/16): 716-22.
47. Malcom R, Olive M, Lechner W. The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials; Guidance for clinical practice. Expert Opin Drug Saf 2008; 7(4): 459-72.
48. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986; 256(11): 1449-55.
49. Chick J, Gough K, Falkowski W, et al. Disulfiram treatment of alcoholism. Br J Psychiatry 1992; 161: 84-9.
50. Gerrein JR, Rosenberg CM, Manohar V. Disulfiram maintenance in outpatient treatment of alcoholism. Arch Gen Psychiatry 1973; 28(6): 798-802.
51. Azrin NH, Sisson RW, Meyers R, et al. Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiatry 1982; 13(2): 105-12.
52. O'Farrell TJ, Bayog RD. Antabuse contracts for married alcoholics and their spouses: a method to maintain antabuse ingestion and decrease conflict about drinking. J Subst Abuse Treat 1986; 3(1): 1-8.
53. O'Farrell TJ, Cutter H, Floyd F. Evaluating behavioral marital therapy for male alcoholics: Effects on marital adjustment and communication from before to after treatment. Behav Ther 1985; 16: 147-67.
54. Lundwall L, Baekeland F. Disulfiram treatment of alcoholism. J Nerv Ment Dis 1971; 153(6): 381-94.
55. Wright C, More R. Disulfiram treatment of alcoholism. Am J Med 1990; 88: 647-55.
56. Brewer C. Recent developments in disulfiram treatment. Alcohol Alcohol 1993; 28(4): 383-95.
57. Kristenson H. How to get the best out of Antabuse. Alcohol Alcohol 1995; 30(6): 775-83.
58. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 1999; 20(5): 427-35.
59. Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999; 340(19): 1482-90.
60. Brewer C, Meyers RJ, Johnsen J. Does disulfiram help to prevent relapse in alcohol abuse? CNS Drugs 2000; 14(5): 329-41.
61. Ritvo J, Park C. The psychiatric management of patients with alcohol dependence. Curr Treat Opt Neurol 2007; 9: 381-92.
62. Miller WR, Brown JM, Simpson TL, et al. What works? A methodological analysis of the alcohol treatment outcome literature. In: Hester RK, Miller WR, Eds. Handbook of alcoholism treatment approaches: effective alternatives. 2nd ed. Boston: Allyn and Bacon 1995; pp. 12-44.
63. Miller WR, Wilbourne PL. Mesa Grande: A methodological analysis of clinical trials of treatment for alcohol use disorders. Addiction 2002; 97(3): 265-77.
64. Haynes SN. Contingency management in a municipally-administered Antabuse program for alcoholics. J Behav Ther Exp Psychiatry 1973; 4: 31-2.
65. Carroll KM, Nich C, Ball SA, et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998; 93(5): 713-28.
66. Robichaud C, Strickler D, Bigelow G, et al. Disulfiram maintenance employee alcoholism treatment: a three-phase evaluation. Behav Res Ther 1979; 17: 618-21.
67. Tønnesen H, Rosenberg J, Nielsen H, et al. Effect of preoperative abstinence on poor postoperative outcome in alcohol misusers: randomised controlled trial. BMJ 1999; 318: 1311-6.
68. Martin B, Clapp L, Bialkowski D, et al. Compliance to supervised disulfiram therapy: A comparison of voluntary and court-ordered patients. Am J Addict 2003; 12: 137-43.
69. Martin B, Clapp L, Alfers J, et al. Adherence to court-ordered disulfiram at fifteen months: A naturalistic study. J Subst Abuse Treat 2004; 26: 233-6.
70. Martin B, Alfers J, Kulig C, et al. Disulfiram therapy in patients with hepatitis C: A 12-months, controlled follow-up study. J Stud Alcohol 2004; 65: 651-7.
71. Mueser KT, Noordsy DL, Fox L, et al. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 2003; 12(3): 242- 52.
72. Niederhofer H, Staffen W. Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents. Drug Alcohol Rev 2003; 22(3): 295-7.
73. Neto D, Lambaz R, Tavares J. Compliance with aftercare treatment, including disulfiram, and effect on outcome in alcoholdependent patients. Alcohol Alcohol 2007; 42(6): 604-9.
74. Fuller RK, Gordis E. Disulfiram in the treatment of drinking problems: a response to commentaries. Addiction 2004; 99(1): 27- 8.
75. Liskow B, Nickel EJ, Tunley N, et al. Alcoholics' attitudes toward and experiences with disulfiram. Am J Drug Alcohol Abuse 1990; 16: 147-60.
76. Børup C, Kaiser A, Jensen E. Long-term Antabuse treatment: Tolerance and reasons for withdrawal. Acta Psychiatr Scand 1992; 86(Suppl 369): 47-9.
77. Enghusen-Poulsen H, Loft S, Anderson JR, Anderson M. Disulfiram therapy- adverse drug reactions and interactions. Acta Psychiatr Scand 1992; 86: 59-66.
78. Friis H, Andreasen P. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on adverse drug reactions between 1978 and 1987. J Intern Med 1992; 232: 133-8.
79. Verge C, Lucena M, López-Torres E, et al. Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: Is there still a role for these drugs? World J Gastroenterol 2006; 12(31): 5078-80.
80. Becker M, Sugarman G. Death following "test drink" of alcohol inpatients receiving Antabuse. JAMA 1952; 149: 568-9.
81. Jacobsen E. Deaths of alcoholic patients treated with disulfiram (Tetraethylthiuram Disulfide) in Denmark. Q J Stud Alcohol 1952; 13: 16-26.
82. Ojehagen A, Skjaerris A, Berglund M. Long-term use of aversive drugs in outpatient alcoholism treatment. Acta Psychiatr Scand 1991; 84(2): 185-90.
83. Altun G, Alter A, Erdogan O. Acute myocardial infarction due to disulfiram (Antabus)-Alcohol interaction. Cardiovasc Drugs Ther 2006; 20: 391-2.
84. Caci H, Baylé F. A case of disulfiram-methylphenidate interaction: Implications for treatment. Am J Psychiatry 2007; 164(11): 1759.
85. Ceylan M, Turkcan A, Mutlu E, et al. Manic episode with psychotic symptoms associated with high dose of disulfiram. J Clin Psychopharmacol 2007; 27: 224-5.
86. Fan C, Lin S, Huang M. Disulfiram-induced punding. J Clin Psychopharmacol 2008; 28(4): 473-4.
87. Filosto M, Tentorio M, Broglio L, et al. Disulfiram neuropathy: Two cases of distal axonopathy. Clin Toxicol 2008; 46: 314-6
88. Li MY, Shen YC. Manic episode with psychosis following a lower than recommended regimen of disulfiram. Prog Neuropsychopharmacol Biol Psychiatry 2007; 32: 311-2.
89. Mattes J. Antabuse reaction with Ceftin. Am J Psychiatry 2006; 163(11): 2019-20.
90. Mirsal H, Yalug I, Tan D, et al. Delirium-associated disulfiram and ethanol interactions. Prim Care Compan J Clin Psychiatry 2005; 7(5): 235-7.
91. Orakzai A, Guerin M, Beatty S. Disulfiram-induced transient optic and peripheral neuropathy: a case report. Ir J Med Sci 2007; 176: 319-21.
92. Zawar V, Nerlikar S. Dermatitis recall during disulfiram therapy. Indian J Dermatol Venerol Leprol 2004; 70(1): 33-5.
93. Milne H, Parke T. Hypotension and ST depression as a result of disulfiram ethanol reaction. Eur J Emerg Med 2007; 14: 228-9.
94. Lachenmeier D, Kanteres F, Rehm J. Carcinogenicity of acetaldehyde in alcoholic beverages: risk assessment outside ethanol metabolism. Addiction 2009; 104: 533-50.
95. Salaspuro M. Acetaldehyde: a cumulative carcinogen in humans. Addiction 2009; 104: 551-3.
96. Schmidt W, de Lint J. Causes of deaths of alcoholics. Q J Stud Alcohol 1972; 33: 171-85.
97. Berglund M. Mortality in alcoholics related to clinical state at first admission. Acta Psychiatr Scand 1984; 70: 407-16.
98. Baan R, Straif K, Grosse Y, et al. Carcinogenicity of alcoholic beverages. Lancet Oncol 2007; 8: 292-3.
99. Bagnardi V, Blangiardo M, La Vecchia C, et al. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer 2001; 85(11): 1700-5.
100. Ehrenreich H, Mangholz A, Schmitt M, et al. OLITA: an alternative in the treatment of therapy-resistant chronic alcoholics. First evaluation of a new approach. Eur Arch Psychiatry Clin Neurosci 1997; 247(1): 51-4.
101. Krampe H, Wagner T, Küfner H, et al. Therapist rotation - a new element in the outpatient treatment of alcoholism. Subst Use Misuse 2004; 39(1): 135-78.
102. Krampe H, Stawicki S, Ribbe K, et al. Development of an outcome prediction measure for alcoholism therapy by multimodal monitoring of treatment processes. J Psychiatr Res 2008; 43: 30-47.
103. Andersen M. Lack of bioequivalence between disufiram formulations. Acta Psychiatr Scand 1992; 86: 31-5.
104. Christensen J, Rønsted P, Vaag U. Side effects after disulfiram: Comparison of disulfiram and placebo in a double-blind multicentre study. Acta Psychiatr Scand 1984; 69: 265-73.
105. Petersen E. The pharmacology and toxicology of disulfiram and its metabolites. Acta Psychiatr Scand 1992; 86: 7-13.
106. Johansson B. A review of pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand 1992; 86: 15-26.